Loading AKTS detail
Aktis Oncology, Inc. operates as a clinical-stage oncology company that engages in the development of targeted radiopharmaceutical therapies for cancer treatment.
The company offers a miniprotein radioconjugate platform to discover and develop radiopharmaceutical therapies that deliver the tumor-killing properties of radioisotopes. It offers Nectin-4, a miniprotein radioconjugate for the treatment of locally advanced or metastatic urothelial cancer. Its products include AKY-1189 to deliver a radioisotope to Nectin-4 expressing tumors for the treatment of metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and AKY-2519 to deliver radioisotope to B7-H3 CD276 expressing tumors targeting prostate, lung and other solid tumors. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020.
Aktis Oncology, Inc. was incorporated in 2020 and is based in Boston, Massachusetts.
Chart data unavailable

BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platform technologies, today announced the U.S. Food and Drug Administration (FDA) cleared the Investigational New Drug (IND) applications for the Company to proceed to a Phase 1b clinical trial with AKY-25191. AKY-2519 is a miniprotein radioconjugate targeting B7-H3, which is expressed in several solid tumor types including prostate and lung cancers, and is the second clinical stage miniprotein radioconjugate discovered using Aktis' proprietary platform. The Company's lead miniprotein radioconjugate, AKY-1189, targeting Nectin-4, is currently enrolling patients in a Phase 1b clinical study. Aktis' miniprotein radioconjugates are designed to selectively deliver actinium-225 (225Ac), a highly potent alpha-emitting radioisotope, to target-expressing tumors. The Company also provided business updates and reported financial results for the year ended December 31, 2025.

BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies, today announced that Matthew Roden, Ph.D., President and Chief Executive Officer of Aktis Oncology, will present at the following investor conferences in March 2026.

BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AKY-1189 for the treatment of adult patients with locally advanced or metastatic urothelial cancer (mUC) who have progressed on or after prior systemic therapies. Generated using Aktis' miniprotein radioconjugate platform, AKY-1189 is designed to deliver actinium-225 (225Ac), a highly potent alpha-emitting radioisotope, to Nectin-4 expressing tumors. Approximately 80 – 90% of urothelial cancer patients show positive expression of Nectin-4.

In the past week, a beneficial owner has continued to build a stake in insurance giant W.R.

Guru Stock PicksAndreas Halvorsen has made the following transactions:Add in RRX by 5.71%Stock News Verizon service outage hits users: Verizon (VZ) reported a w

For speculative investors, the start of each year is always a good time to revisit an initial public offering (IPO) calendar. Almost every week, companies go public, with a handful of them offering considerable short-term upside potential.

Stock News Saks Global files Chapter 11: Saks Global (private) sought Chapter 11 protection, citing heavy debt from its 2024 Neiman Marcus deal and inventory st

Guru Stock PicksLarry Robbins has made the following transactions:Add in MYGN by 7.71%Stock News Trump floats 10% cap on card APRs: President Trump proposed a o

BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (“Aktis”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies, today announced the closing of its upsized initial public offering of 17,650,000 shares of its common stock, at an initial public offering price of $18.00 per share, occurred on January 12, 2026. In addition, the underwriters exercised in full their option to purchase an additional 2,647,500 shares of Aktis' common stock, at the initial public offering price of $18.00 per share. The sale of the 2,647,500 additional shares is expected to close on January 14, 2026, subject to satisfaction of customary closing conditions. The aggregate gross proceeds from the initial public offering, including the full exercise of the underwriters' option to purchase additional shares, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $365.4 million. All of the shares of common stock were offered by Aktis. Aktis' common stock began trading on the Nasdaq Global Select Market on January 9, 2026 under the ticker symbol “AKTS.”

Guru Stock PicksJerome Dodson has made the following transactions:Reduce in ORLY by 3%Sold out in BLDRAdd in NTRA by 2.49%New position in INSMTweedy Browne Inte

U.S. IPO Weekly Recap: Aktis Oncology Leads As First Sizable 2026 IPO

Stock News California billionaire tax splits tech leaders: Nvidia (NVDA) CEO Jensen Huang said he's âfineâ with a proposed one-time 5% California wealth tax

Aktis Oncology Inc. (AKTS) drew strong investor demand in its Nasdaq debut, with shares trading at $22.91 as of 12:19 p.m. Friday in New York after pricing its

LOS ANGELES & BOSTON--(BUSINESS WIRE)--Vida Ventures (“Vida”), a next-generation life sciences venture firm, today congratulates Aktis Oncology (Nasdaq: AKTS), a clinical-stage biotechnology company advancing a pipeline of alpha-emitting radiopharmaceuticals for the treatment of solid tumors. Aktis raised $318 million in its initial public offering, reflecting strong investor interest, its recently announced anchor investment by Eli Lilly and Company (NYSE: LLY), and pipeline momentum as the co.

Cancer drug developer Aktis Oncology said on Thursday it priced its upsized U.S. initial public offering at $18 per share, raising about $318 million.